Phase I Study of HL-085 in Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2020-11-12
Target enrollment:
Participant gender:
Summary
The study drug, HL-085 is a MEK inhibitor with the potential indication for cancers. It is an
oral medication to be given daily.
The purposes of this study is to find answers to the following research questions:
1. What is the highest tolerable dose of HL-085 that can be given to subjects when given
orally (by mouth) on a twice daily basis?
2. What are the side effects of HL-085?
3. How much HL-085 is in the blood at specific times after dosing and how does the body get
rid of the HL-085?